Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in EBV-positive Nasopharyngeal Carcinoma
NCT06019130Phase 2Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by German Society for Pediatric Oncology and Hematology. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06019130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019130.